Replies to post #198763 on Biotech Values

[biocqr]

ADXS > Advaxis Provides 2016 Business Outlook

11 Trials Evaluating Lm Technology™ Advance to Hit Multiple Development Milestones

PD-1 and PD-L1 Checkpoint Combination Trials Advance to Second Phases of Evaluation

Phase 3 AIM2CERV Trial to Commence in mid-2016

MINE™ (My Immunotherapy Neo-Epitopes) Progresses to Clinical Evaluation

http://ir.advaxis.com/press-releases/detail/1196